ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/[1-(5-oxo-D-proline)]buserelin
C60H86N16O13
1239.4 g/mol
API

[1-(5-oxo-D-proline)]buserelin

CAS1926163-20-3
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

This compound is a synthetic peptide used as an active pharmaceutical ingredient in pharmaceutical research and manufacturing. Its structure includes multiple amino acid residues, amide bonds, and aromatic rings, contributing to its complex molecular architecture.

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing [1-(5-oxo-D-proline)]buserelin?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ReferenceSame Category

(Des-Gly10,D-Trp3,D-Leu6,Pro-NHEt9)-LHRH Trifluoroacetate

CAS1926163-23-6

pharmaceutical raw material

ReferenceSame Category

Leuprolide EP impurity D

CAS1926163-25-8

pharmaceutical raw material

ReferenceSame Category

Goserelin Impurity G

CAS1926163-37-2

pharmaceutical raw material

ReferenceSame Category

(D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH

CAS1926163-38-3

pharmaceutical raw material

Referencestereoisomer of

Buserelin EP Impurity B

CAS1926163-21-4

pharmaceutical raw material

Referencestereoisomer of

Buserelin

CAS57982-77-1

pharmaceutical raw material

Referencestereoisomer of

Buserelin acetate

CAS68630-75-1

pharmaceutical raw material

Referencestereoisomer of

(Des-Gly10,D-Tyr5,D-Ser(tBu)6,Pro-NHEt9)-LHRH Acetate

CAS1426174-33-5

pharmaceutical raw material

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

(2R)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

InChIKey

CUWODFFVMXJOKD-UUVJJVFOSA-N

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H]6CCC(=O)N6

Synonyms (5)
  • Buserelin EP Impurity E (Free Base)
  • BUSERELIN IMPURITY E

Sourcing [1-(5-oxo-D-proline)]buserelin?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→